Group 1 - FinancialApps has filed a $100 million lawsuit against Envestnet for trade secret misappropriation, tortious interference, and unfair competition, which is now proceeding to a jury trial in Delaware Federal Court [1] - Envestnet's defamation counterclaim against FinancialApps was dismissed, and the motion for summary judgment on FinancialApps's claims was denied by Judge Jennifer L. Hall [2] - The legal team representing FinancialApps is led by Marc E. Kasowitz from Kasowitz Benson Torres LLP, who expressed satisfaction with the court's decisions and readiness for trial [3] Group 2 - Envestnet is currently involved in a $4.5 billion acquisition deal with Bain Capital, which has been approved by shareholders [1]

BERWYN, Pa., Sept. 24, 2024 /PRNewswire/ -- Envestnet, Inc. (NYSE: ENV) ("Envestnet," or the "Company"), a leading provider of integrated technology, data intelligence, and wealth solutions, today announced that, at a special meeting (the "Special Meeting"), the Company's stockholders approved the pending acquisition of the Company by affiliates of vehicles managed or advised by Bain Capital (the "Merger"). Based on a preliminary tally of voting results, approximately 99.33% of the votes represented at the ...

Core Insights - Kairos Pharma Ltd. has announced a collaboration with PreCheck Health Services to develop companion biomarkers for its cancer therapy ENV105, targeting prostate and lung cancers [1][10] - The partnership aims to enhance patient screening and therapy monitoring in ongoing Phase 1 and Phase 2 clinical trials [1][2] Company Overview - Kairos Pharma is a clinical-stage biopharmaceutical company focused on oncology therapeutics, utilizing structural biology to address drug resistance and immune suppression [8] - The company is based in Los Angeles, California, and is committed to improving patient outcomes through innovative treatment options [8] Collaboration Details - The collaboration will utilize advanced molecular diagnostics to validate and develop biomarkers identified in previous clinical trials, aiming for a personalized approach to cancer care [2][6] - PreCheck Health Services will analyze biopsy tissues and circulating tumor cells from patients in ongoing trials, including a Phase 2 trial for prostate cancer and a Phase 1 trial for lung cancer [2][4] Clinical Trials - Two key clinical trials are highlighted: - NCT05401110, a Phase 1 trial for EGFR-driven lung cancer patients resistant to osimertinib, focusing on gene expression profiling [4] - NCT05534646, a Phase 2 trial for castrate-resistant prostate cancer patients, concentrating on profiling circulating tumor cells and tumor biopsies [4][5] Companion Diagnostics Development - A significant outcome of the partnership is the development of a companion diagnostic for ENV105, which will include a three-gene PCR analysis to predict patient responses [6] - This diagnostic aims for FDA approval to guide patient selection for Phase 3 clinical trials [6] Technological Integration - The collaboration will leverage PreCheck's SolidTumorCheck+ platform for gene expression profiling of tumor biopsies, potentially leading to non-invasive liquid biopsy tests for future patient screening [3][7] - The integration of biomarkers and liquid biopsy technologies is expected to enhance treatment precision and improve patient outcomes [7][10]

BERWYN, Pa., Sept. 23, 2024 /PRNewswire/ -- Envestnet (NYSE: ENV), a leading provider of integrated technology, data intelligence, and wealth solutions, has been recognized as an industry leader at the 2024 WealthManagement.com Industry Awards (the "Wealthies"). Including its Exchanges and partner integrations, Envestnet's ecosystem won five awards, including top honors for Advisor Choice and Best Unified (All-in-One) System. Now in its 10th year, the WealthManagement.com Industry Awards aims to honor outst ...

Core Insights - Envestnet is enhancing its wealth management platform for Registered Investment Advisors (RIAs) with new features aimed at streamlining workflows and improving client engagement [3][4][5] Group 1: New Features and Capabilities - The new Order Blotter Tool simplifies fixed-income trade management, providing centralized oversight and automated reconciliation, addressing a major pain point for advisors [5] - The updated Client Portal consolidates client accounts into a user-friendly interface, available on mobile devices, allowing advisors to manage assets and track goals efficiently [9] - Envestnet RIA Trading is now available as a standalone product, integrating seamlessly with Envestnet Managed Accounts, enabling better management of UMA sleeve allocations [7] Group 2: Market Position and Usage - Envestnet's RIA platform is utilized by over 2,700 independent RIA firms managing more than $1.9 trillion in assets, and it has been ranked No. 1 for Trading/Rebalancing Tools in the 2024 T3/Inside Information Advisor Survey [6] - The RIA Marketplace, launching on October 1, will provide access to fund strategist portfolios managed by reputable asset managers without a platform fee, enhancing advisors' ability to deliver solutions at scale [10] Group 3: Strategic Focus and Industry Impact - Envestnet aims to support the growth and productivity of RIAs through its technology solutions, focusing on optimizing advisor workflows to allow more time for client relationships [4] - The company has been serving the wealth management industry for 25 years, with over $6.2 trillion in platform assets, indicating a strong market presence and commitment to innovation [14]

Envestnet, Inc.'s (ENV) shares have gained 26.7% year to date compared with a 9.1% rise of the industry and an 18.4% increase of the Zacks S&P 500 composite. What's Behind the Rally ENV put on an impressive earnings performance history. Its earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missed once, with an average surprise of 6.2%. Envestnet is focused on increasing its share of the addressable market consisting of enterprise clients in wealth management, financi ...

SAN DIEGO, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Johnson Fistel, LLP, a leading stockholder rights law firm, announced today that it has initiated an investigation into the board members of Envestnet, Inc. (NYSE: ENV) concerning potential breaches of fiduciary duties related to the proposed sale of the Company to private equity firm Bain Capital. On July 11, 2024, Envestnet informed the public that it has agreed to a deal with Bain Capital, in which stockholders will receive $63.15 per share in an all-cash offe ...

Recognition Spans 'All-In-One' Platforms, Innovation, Direct Indexing, Retirement, and Annuities Showcasing Envestnet's Comprehensive Solutions and Integrations BERWYN, Pa., Aug. 27, 2024 /PRNewswire/ -- Envestnet (NYSE: ENV), a leading provider of integrated technology, data intelligence, and wealth solutions, announced that its ecosystem has been recognized as a finalist for seven 2024 Wealth Management Industry Awards ("Wealthies"). Envestnet's ecosystem received the highest number of finalists from a fi ...

Envestnet, Inc. (ENV) reported mixed second-quarter 2024 results, wherein earnings missed the Zacks Consensus Estimate, while revenues surpassed the same. The stock price has not witnessed any significant impact of the earnings miss since the company released results on Aug 9, 2024. ENV's earnings per share were 55 cents, missing the Zacks Consensus Estimate by 12.7%. The bottom line increased 19.6% year over year from the second quarter of 2023. Total revenues of $348.3 million beat the consensus estimate ...

NEW YORK, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Kellanova (NYSE: K)'s sale to Mars, Incorporated for $83.50 per share in cash. If you are a Kellanova shareholder, click here to learn more about your legal rights and options. Envestnet, Inc. (NYSE: ENV)'s sale to Bain Capital for $63.15 in cash per share. I ...